Fennec Pharmaceuticals Inc.
NASDAQ:FENCBiotechnology
-$0.12 today
- Market cap
- $470.62M
- Beta
- 1.08
- P/E (TTM)
- -36.3
- EPS (TTM)
- -$0.24
Volume 0.59M
Average 0.26M
Returns on capital
Fennec Pharmaceuticals Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-27.8%
avg 44.3%
ROIC
-10.7%
avg -84.2%
ROA
-13.9%
avg -53.9%
Analysis
ROIC is currently the strongest return metric at -10.7% versus its period average of -84.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Jeffrey S. Hackman | Chief Executive Officer & Director | USD 632.18K | 63 | 70.84K | 0.25% |
Robert C. Andrade | Chief Financial Officer | USD 552.65K | 51 | — | — |
Pierre S. Sayad | Chief Medical Officer | USD 464.08K | — | — | — |
Lei Fang | President of Pharstat Inc | — | — | — | — |
Mark Gowland | Controller | — | — | — | — |
Terry Evans | Chief Commercial Officer | — | — | — | — |
Christiana Cioffi | Chief Strategy Officer | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 31, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
16
$9.79M
Net Transaction Value
−$9.79M
Net selling
Most Active
Raykov Rosty
10 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Sep 15, 26Sep 15, 2026 | Brughera Marco Maria Direct | Sell | $160K$159,958.05 |
| Sep 1, 26Sep 1, 2026 | Raykov Rosty Direct | Sell | $121.1K$121,100.00 |
| Aug 31, 26Aug 31, 2026 | Sayad Pierre Sargis Direct | Sell | $146.2K$146,160.00 |
| Aug 27, 26Aug 27, 2026 | Andrade Robert Direct | Sell | $883.5K$883,500.00 |
| Aug 3, 26Aug 3, 2026 | Raykov Rosty Direct | Sell | $95.8K$95,800.00 |
| Jul 1, 26Jul 1, 2026 | Raykov Rosty Direct | Sell | $99.9K$99,925.59 |
| Jun 1, 26Jun 1, 2026 | Raykov Rosty Direct | Sell | $93.8K$93,766.14 |
| May 11, 26May 11, 2026 | RALLIS CHRIS A Direct | Sell | $58.8K$58,755.84 |
| May 1, 26May 1, 2026 | Raykov Rosty Direct | Sell | $69.8K$69,753.07 |
| Apr 1, 26Apr 1, 2026 | Raykov Rosty Direct | Sell | $69.1K$69,069.26 |
1–10 of 16
Summary
Insiders reported 0 buys worth $0.00 and 16 sells worth $9.79M over the last 12 months. That adds up to net selling of $9.79M. Raykov Rosty was the most active insider with 10 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +207.5% | +40.1% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at +207.5% over three years. Forward estimates point to Revenue at +40.1% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Fennec Pharmaceuticals Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Eupraxia Pharmaceuticals Inc.
NASDAQ:EPRX
Market cap
$548.02M
Avalo Therapeutics, Inc.
NASDAQ:AVTX
Market cap
$448.71M
Orchestra BioMed Holdings, Inc.
NASDAQ:OBIO
Market cap
$435.76M
Enanta Pharmaceuticals, Inc.
NASDAQ:ENTA
Market cap
$320.09M
Nautilus Biotechnology, Inc.
NASDAQ:NAUT
Market cap
$295.50M
Prelude Therapeutics Incorporated
NASDAQ:PRLD
Market cap
$275.32M
Cartesian Therapeutics, Inc.
NASDAQ:RNAC
Market cap
$193.69M
Black Diamond Therapeutics, Inc.
NASDAQ:BDTX
Market cap
$84.48M
Caribou Biosciences, Inc.
NASDAQ:CRBU
Market cap
$39.10M
Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARD
Market cap
$29.11M
Questions
Management questions
Common questions about FENC's management, answered from reported figures.
Who manages FENC?
Fennec Pharmaceuticals Inc. (FENC) lists 7 active executives. The top listed executive is Pierre S. Sayad, Chief Medical Officer.
Are FENC insiders buying or selling?
Recent insider activity shows net selling of $6.87M.
Continue the stock analysis
Jump to another research area for this company.